New cocktail of drugs and viruses aims to shrink rectal tumors without surgery
NCT ID NCT07543848
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a mix of immunotherapy, a cancer-killing virus, short-course radiation, and chemotherapy in 20 people with locally advanced low rectal cancer. The goal is to see if this combination can make the tumor disappear completely for at least a year, potentially allowing patients to avoid major surgery. The study will closely monitor tumor response and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
serplulimab (PD-1 inhibitor), oncolytic virus H101, short-course radiotherapy, and XELOX chemotherapy
What this could lead to
If successful, this combination could increase the chance of a complete response and allow more patients to avoid surgery, preserving the rectum.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply widely. The combination of multiple treatments also raises the risk of serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, 400030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••